12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Lexaria has completed its submission to the human research ethics committee ("HREC") for its planned addition of Study Arm 5 ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic ...

Katz, M.D., of the John A. Moran Eye Center at University of Utah Health, saw a patient who experienced sudden painless vision loss after starting semaglutide. The patient stopped using the drug ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...

Can GLP-1 Meds Harm Your Eyes ... who were taking GLP-1s such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound). Seven of the nine patients developed a condition known as ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally ... compared to other antidiabetic drugs. 4 These observations were based on 100 million patient records ...

Past studies have found a potential link between semaglutide and the eye condition ... it’s important for researchers to continue to examine how GLP-1 medications might impact other areas ...

Are you a print subscriber? Activate your account. By Tim Nudd - 19 hours 17 min ago By Amir Farhang - 19 hours 17 min ago By Ashley Joseph - 1 day 17 hours ago By Ad Age Staff - 1 day 17 hours ...

Like most drugs, Mounjaro can cause side effects. Hair loss was not a reported side effect of Mounjaro, but it was reported with other GLP-1 agonists. Mounjaro can cause side effects, such as ...

Now, diabetes specialists and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight. In many ways, it's easier for physicians to access these drugs.